APO Research
Talk to an analyst

APO RESEARCH · REPORT

CAR T-Cell-Based Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global CAR T-Cell-Based Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

21 December 2025198 pages

Choose your research edition.

Industry ResearchCAR T-Cell-Based Drug Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal CAR T-Cell-Based Drug Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal CAR T-Cell-Based Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal CAR T-Cell-Based Drug Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal CAR T-Cell-Based Drug Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global CAR T-Cell-Based Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for CAR T-Cell-Based Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for CAR T-Cell-Based Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for CAR T-Cell-Based Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for CAR T-Cell-Based Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of CAR T-Cell-Based Drug include J & J, Novartis, Gilead Sciences, Bristol-Myers Squibb, Sorrento Therapeutics, Mustang Bio, JW Therapeutics, FOSUNKite and Celyad, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global CAR T-Cell-Based Drug market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of CAR T-Cell-Based Drug and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents CAR T-Cell-Based Drug revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the CAR T-Cell-Based Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

CAR T-Cell-Based Drug Segment by Company

J & J

Novartis

Gilead Sciences

Bristol-Myers Squibb

Sorrento Therapeutics

Mustang Bio

JW Therapeutics

FOSUNKite

Celyad

Cellectis

CARsgen Therapeutics

Bluebird Bio

Autolus Therapeutics

Allogene Therapeutics

CAR T-Cell-Based Drug Segment by Type

CD19-targeted

BCMA-targeted

CAR T-Cell-Based Drug Segment by Application

Lymphoma

Multiple Myeloma

CAR T-Cell-Based Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CAR T-Cell-Based Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of CAR T-Cell-Based Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CAR T-Cell-Based Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of CAR T-Cell-Based Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global CAR T-Cell-Based Drug industry.

Chapter 3: Detailed analysis of CAR T-Cell-Based Drug companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, CAR T-Cell-Based Drugrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global CAR T-Cell-Based Drug Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of CD19-targeted Table 3. Key Players of BCMA-targeted Table 4. Global CAR T-Cell-Based Drug Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Lymphoma Table 6. Key Players of Multiple Myeloma Table 7. Global CAR T-Cell-Based Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 8. Global CAR T-Cell-Based Drug Market Size by Region (2021-2026) & (US$ Million) Table 9. Global CAR T-Cell-Based Drug Market Share by Region (2021-2026) Table 10. Global CAR T-Cell-Based Drug Market Size by Region (2027-2032) & (US$ Million) Table 11. Global CAR T-Cell-Based Drug Market Share by Region (2027-2032) Table 12. CAR T-Cell-Based Drug Industry Trends Table 13. CAR T-Cell-Based Drug Industry Drivers Table 14. CAR T-Cell-Based Drug Industry Opportunities and Challenges Table 15. CAR T-Cell-Based Drug Industry Restraints Table 16. Global CAR T-Cell-Based Drug Revenue by Company (US$ Million) & (2021-2026) Table 17. Global CAR T-Cell-Based Drug Revenue Market Share by Company (2021-2026) Table 18. Global CAR T-Cell-Based Drug Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 19. Global CAR T-Cell-Based Drug Key Company Head Office and Area Served Table 20. Global CAR T-Cell-Based Drug Company, Product Type & Application Table 21. Global CAR T-Cell-Based Drug Company Establishment Date Table 22. Global Company Market Concentration Ratio (CR5 and HHI) Table 23. Global CAR T-Cell-Based Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 24. Global CAR T-Cell-Based Drug Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global CAR T-Cell-Based Drug Market Size by Type (2021-2026) & (US$ Million) Table 26. Global CAR T-Cell-Based Drug Market Size by Type (2027-2032) & (US$ Million) Table 27. Global CAR T-Cell-Based Drug Revenue Market Share by Type (2021-2026) Table 28. Global CAR T-Cell-Based Drug Revenue Market Share by Type (2027-2032) Table 29. Global CAR T-Cell-Based Drug Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global CAR T-Cell-Based Drug Market Size by Application (2021-2026) & (US$ Million) Table 31. Global CAR T-Cell-Based Drug Market Size by Application (2027-2032) & (US$ Million) Table 32. Global CAR T-Cell-Based Drug Revenue Market Share by Application (2021-2026) Table 33. Global CAR T-Cell-Based Drug Revenue Market Share by Application (2027-2032) Table 34. J & J Company Information Table 35. J & J Business Overview Table 36. J & J CAR T-Cell-Based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 37. J & J CAR T-Cell-Based Drug Product Portfolio Table 38. J & J Recent Development Table 39. Novartis Company Information Table 40. Novartis Business Overview Table 41. Novartis CAR T-Cell-Based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Novartis CAR T-Cell-Based Drug Product Portfolio Table 43. Novartis Recent Development Table 44. Gilead Sciences Company Information Table 45. Gilead Sciences Business Overview Table 46. Gilead Sciences CAR T-Cell-Based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Gilead Sciences CAR T-Cell-Based Drug Product Portfolio Table 48. Gilead Sciences Recent Development Table 49. Bristol-Myers Squibb Company Information Table 50. Bristol-Myers Squibb Business Overview Table 51. Bristol-Myers Squibb CAR T-Cell-Based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Bristol-Myers Squibb CAR T-Cell-Based Drug Product Portfolio Table 53. Bristol-Myers Squibb Recent Development Table 54. Sorrento Therapeutics Company Information Table 55. Sorrento Therapeutics Business Overview Table 56. Sorrento Therapeutics CAR T-Cell-Based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Sorrento Therapeutics CAR T-Cell-Based Drug Product Portfolio Table 58. Sorrento Therapeutics Recent Development Table 59. Mustang Bio Company Information Table 60. Mustang Bio Business Overview Table 61. Mustang Bio CAR T-Cell-Based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Mustang Bio CAR T-Cell-Based Drug Product Portfolio Table 63. Mustang Bio Recent Development Table 64. JW Therapeutics Company Information Table 65. JW Therapeutics Business Overview Table 66. JW Therapeutics CAR T-Cell-Based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. JW Therapeutics CAR T-Cell-Based Drug Product Portfolio Table 68. JW Therapeutics Recent Development Table 69. FOSUNKite Company Information Table 70. FOSUNKite Business Overview Table 71. FOSUNKite CAR T-Cell-Based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. FOSUNKite CAR T-Cell-Based Drug Product Portfolio Table 73. FOSUNKite Recent Development Table 74. Celyad Company Information Table 75. Celyad Business Overview Table 76. Celyad CAR T-Cell-Based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Celyad CAR T-Cell-Based Drug Product Portfolio Table 78. Celyad Recent Development Table 79. Cellectis Company Information Table 80. Cellectis Business Overview Table 81. Cellectis CAR T-Cell-Based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. Cellectis CAR T-Cell-Based Drug Product Portfolio Table 83. Cellectis Recent Development Table 84. CARsgen Therapeutics Company Information Table 85. CARsgen Therapeutics Business Overview Table 86. CARsgen Therapeutics CAR T-Cell-Based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 87. CARsgen Therapeutics CAR T-Cell-Based Drug Product Portfolio Table 88. CARsgen Therapeutics Recent Development Table 89. Bluebird Bio Company Information Table 90. Bluebird Bio Business Overview Table 91. Bluebird Bio CAR T-Cell-Based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 92. Bluebird Bio CAR T-Cell-Based Drug Product Portfolio Table 93. Bluebird Bio Recent Development Table 94. Autolus Therapeutics Company Information Table 95. Autolus Therapeutics Business Overview Table 96. Autolus Therapeutics CAR T-Cell-Based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 97. Autolus Therapeutics CAR T-Cell-Based Drug Product Portfolio Table 98. Autolus Therapeutics Recent Development Table 99. Allogene Therapeutics Company Information Table 100. Allogene Therapeutics Business Overview Table 101. Allogene Therapeutics CAR T-Cell-Based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 102. Allogene Therapeutics CAR T-Cell-Based Drug Product Portfolio Table 103. Allogene Therapeutics Recent Development Table 104. North America CAR T-Cell-Based Drug Market Size by Type (2021-2026) & (US$ Million) Table 105. North America CAR T-Cell-Based Drug Market Size by Type (2027-2032) & (US$ Million) Table 106. North America CAR T-Cell-Based Drug Market Size by Application (2021-2026) & (US$ Million) Table 107. North America CAR T-Cell-Based Drug Market Size by Application (2027-2032) & (US$ Million) Table 108. North America CAR T-Cell-Based Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 109. North America CAR T-Cell-Based Drug Market Size by Country (2021-2026) Table 110. North America CAR T-Cell-Based Drug Market Size by Country (2027-2032) Table 111. Europe CAR T-Cell-Based Drug Market Size by Type (2021-2026) & (US$ Million) Table 112. Europe CAR T-Cell-Based Drug Market Size by Type (2027-2032) & (US$ Million) Table 113. Europe CAR T-Cell-Based Drug Market Size by Application (2021-2026) & (US$ Million) Table 114. Europe CAR T-Cell-Based Drug Market Size by Application (2027-2032) & (US$ Million) Table 115. Europe CAR T-Cell-Based Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 116. Europe CAR T-Cell-Based Drug Market Size by Country (2021-2026) Table 117. Europe CAR T-Cell-Based Drug Market Size by Country (2027-2032) Table 118. China CAR T-Cell-Based Drug Market Size by Type (2021-2026) & (US$ Million) Table 119. China CAR T-Cell-Based Drug Market Size by Type (2027-2032) & (US$ Million) Table 120. China CAR T-Cell-Based Drug Market Size by Application (2021-2026) & (US$ Million) Table 121. China CAR T-Cell-Based Drug Market Size by Application (2027-2032) & (US$ Million) Table 122. Asia CAR T-Cell-Based Drug Market Size by Type (2021-2026) & (US$ Million) Table 123. Asia CAR T-Cell-Based Drug Market Size by Type (2027-2032) & (US$ Million) Table 124. Asia CAR T-Cell-Based Drug Market Size by Application (2021-2026) & (US$ Million) Table 125. Asia CAR T-Cell-Based Drug Market Size by Application (2027-2032) & (US$ Million) Table 126. Asia CAR T-Cell-Based Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 127. Asia CAR T-Cell-Based Drug Market Size by Country (2021-2026) Table 128. Asia CAR T-Cell-Based Drug Market Size by Country (2027-2032) Table 129. South America, Middle East & Africa CAR T-Cell-Based Drug Market Size by Type (2021-2026) & (US$ Million) Table 130. South America, Middle East & Africa CAR T-Cell-Based Drug Market Size by Type (2027-2032) & (US$ Million) Table 131. South America, Middle East & Africa CAR T-Cell-Based Drug Market Size by Application (2021-2026) & (US$ Million) Table 132. South America, Middle East & Africa CAR T-Cell-Based Drug Market Size by Application (2027-2032) & (US$ Million) Table 133. South America, Middle East & Africa CAR T-Cell-Based Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 134. South America, Middle East & Africa CAR T-Cell-Based Drug Market Size by Country (2021-2026) Table 135. South America, Middle East & Africa CAR T-Cell-Based Drug Market Size by Country (2027-2032) Table 136. Research Programs/Design for This Report Table 137. Authors List of This Report Table 138. Secondary Sources Table 139. Primary Sources List of Figures Figure 1. CAR T-Cell-Based Drug Product Image Figure 2. Global CAR T-Cell-Based Drug Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global CAR T-Cell-Based Drug Market Share by Type: 2025 VS 2032 Figure 4. CD19-targeted Image Figure 5. BCMA-targeted Image Figure 6. Global CAR T-Cell-Based Drug Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 7. Global CAR T-Cell-Based Drug Market Share by Application: 2025 VS 2032 Figure 8. Lymphoma Image Figure 9. Multiple Myeloma Image Figure 10. Global CAR T-Cell-Based Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global CAR T-Cell-Based Drug Market Size (2021-2032) & (US$ Million) Figure 12. Global CAR T-Cell-Based Drug Market Share by Region: 2025 VS 2032 Figure 13. Years Considered Figure 14. Global CAR T-Cell-Based Drug Market Share by Players in 2025 Figure 15. Global Top 5 and 10 CAR T-Cell-Based Drug Players Market Share by Revenue in 2025 Figure 16. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global CAR T-Cell-Based Drug Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global CAR T-Cell-Based Drug Revenue Market Share by Type (2021-2032) Figure 19. Global CAR T-Cell-Based Drug Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global CAR T-Cell-Based Drug Revenue Market Share by Application (2021-2032) Figure 21. North America CAR T-Cell-Based Drug Market Size (2021-2032) & (US$ Million) Figure 22. North America CAR T-Cell-Based Drug Market Share by Type (2021-2032) Figure 23. North America CAR T-Cell-Based Drug Market Share by Application (2021-2032) Figure 24. North America CAR T-Cell-Based Drug Market Share by Country (2021-2032) Figure 25. United States CAR T-Cell-Based Drug Market Size (2021-2032) & (US$ Million) Figure 26. Canada CAR T-Cell-Based Drug Market Size (2021-2032) & (US$ Million) Figure 27. Mexico CAR T-Cell-Based Drug Market Size (2021-2032) & (US$ Million) Figure 28. Europe CAR T-Cell-Based Drug Market Size (2021-2032) & (US$ Million) Figure 29. Europe CAR T-Cell-Based Drug Market Share by Type (2021-2032) Figure 30. Europe CAR T-Cell-Based Drug Market Share by Application (2021-2032) Figure 31. Europe CAR T-Cell-Based Drug Market Share by Country (2021-2032) Figure 32. Germany CAR T-Cell-Based Drug Market Size (2021-2032) & (US$ Million) Figure 33. France CAR T-Cell-Based Drug Market Size (2021-2032) & (US$ Million) Figure 34. U.K. CAR T-Cell-Based Drug Market Size (2021-2032) & (US$ Million) Figure 35. Italy CAR T-Cell-Based Drug Market Size (2021-2032) & (US$ Million) Figure 36. Russia CAR T-Cell-Based Drug Market Size (2021-2032) & (US$ Million) Figure 37. Nordic Countries CAR T-Cell-Based Drug Market Size (2021-2032) & (US$ Million) Figure 38. China CAR T-Cell-Based Drug Market Size (2021-2032) & (US$ Million) Figure 39. China CAR T-Cell-Based Drug Market Share by Type (2021-2032) Figure 40. China CAR T-Cell-Based Drug Market Share by Application (2021-2032) Figure 41. Asia CAR T-Cell-Based Drug Market Size (2021-2032) & (US$ Million) Figure 42. Asia CAR T-Cell-Based Drug Market Share by Type (2021-2032) Figure 43. Asia CAR T-Cell-Based Drug Market Share by Application (2021-2032) Figure 44. Asia CAR T-Cell-Based Drug Market Share by Country (2021-2032) Figure 45. Japan CAR T-Cell-Based Drug Market Size (2021-2032) & (US$ Million) Figure 46. South Korea CAR T-Cell-Based Drug Market Size (2021-2032) & (US$ Million) Figure 47. Taiwan CAR T-Cell-Based Drug Market Size (2021-2032) & (US$ Million) Figure 48. Southeast Asia CAR T-Cell-Based Drug Market Size (2021-2032) & (US$ Million) Figure 49. India CAR T-Cell-Based Drug Market Size (2021-2032) & (US$ Million) Figure 50. Australia CAR T-Cell-Based Drug Market Size (2021-2032) & (US$ Million) Figure 51. South America, Middle East & Africa CAR T-Cell-Based Drug Market Size (2021-2032) & (US$ Million) Figure 52. South America, Middle East & Africa CAR T-Cell-Based Drug Market Share by Type (2021-2032) Figure 53. South America, Middle East & Africa CAR T-Cell-Based Drug Market Share by Application (2021-2032) Figure 54. South America, Middle East & Africa CAR T-Cell-Based Drug Market Share by Country (2021-2032) Figure 55. Brazil CAR T-Cell-Based Drug Market Size (2021-2032) & (US$ Million) Figure 56. South Africa CAR T-Cell-Based Drug Market Size (2021-2032) & (US$ Million) Figure 57. Saudi Arabia CAR T-Cell-Based Drug Market Size (2021-2032) & (US$ Million) Figure 58. Turkey CAR T-Cell-Based Drug Market Size (2021-2032) & (US$ Million) Figure 59. Argentina CAR T-Cell-Based Drug Market Size (2021-2032) & (US$ Million) Figure 60. UAE CAR T-Cell-Based Drug Market Size (2021-2032) & (US$ Million) Figure 61. Egypt CAR T-Cell-Based Drug Market Size (2021-2032) & (US$ Million) Figure 62. Chile CAR T-Cell-Based Drug Market Size (2021-2032) & (US$ Million) Figure 63. Research Process Figure 64. Key Executives Interviewed

Scope & coverage.

Types
  • CD19-targeted
  • BCMA-targeted
Applications
  • Lymphoma
  • Multiple Myeloma
Companies covered
  • J & J
  • Novartis
  • Gilead Sciences
  • Bristol-Myers Squibb
  • Sorrento Therapeutics
  • Mustang Bio
  • JW Therapeutics
  • FOSUNKite
  • Celyad
  • Cellectis
  • CARsgen Therapeutics
  • Bluebird Bio
  • Autolus Therapeutics
  • Allogene Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global CAR T-Cell-Based Drug Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 CD19-targeted
  5. 1.2.3 BCMA-targeted
  6. 1.3 Market Analysis by Application
  7. 1.3.1 Global CAR T-Cell-Based Drug Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  8. 1.3.2 Lymphoma
  9. 1.3.3 Multiple Myeloma
  10. 1.4 Global Market Growth Prospects
  11. 1.5 Global CAR T-Cell-Based Drug Growth Trends by Region
  12. 1.5.1 Global CAR T-Cell-Based Drug Market Size by Region: 2021 VS 2025 VS 2032
  13. 1.5.2 CAR T-Cell-Based Drug Market Size by Region (2021-2026)
  14. 1.5.3 CAR T-Cell-Based Drug Market Size by Region (2027-2032)
  15. 1.6 Assumptions and Limitations
  16. 1.7 Study Goals and Objectives
  17. 1.8 Years Considered
2 Global CAR T-Cell-Based Drug Market Dynamics
  1. 2.1 CAR T-Cell-Based Drug Industry Trends
  2. 2.2 CAR T-Cell-Based Drug Industry Drivers
  3. 2.3 CAR T-Cell-Based Drug Industry Opportunities and Challenges
  4. 2.4 CAR T-Cell-Based Drug Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global CAR T-Cell-Based Drug Revenue by Company (2021-2026)
  2. 3.2 Global CAR T-Cell-Based Drug Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global CAR T-Cell-Based Drug Key Company Head office and Area Served
  4. 3.4 Global CAR T-Cell-Based Drug Company, Product Type & Application
  5. 3.5 Global CAR T-Cell-Based Drug Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global CAR T-Cell-Based Drug Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 CAR T-Cell-Based Drug Players Market Share by Revenue in 2025
  9. 3.6.3 2025 CAR T-Cell-Based Drug Tier 1, Tier 2, and Tier 3
4 CAR T-Cell-Based Drug Market by Type
  1. 4.1 Global CAR T-Cell-Based Drug Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global CAR T-Cell-Based Drug Market Size by Type (2021-2032)
  3. 4.3 Global CAR T-Cell-Based Drug Market Size Share by Type (2021-2032)
5 CAR T-Cell-Based Drug Market by Application
  1. 5.1 Global CAR T-Cell-Based Drug Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global CAR T-Cell-Based Drug Market Size by Application (2021-2032)
  3. 5.3 Global CAR T-Cell-Based Drug Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 J & J
  2. 6.1.1 J & J Company Information
  3. 6.1.2 J & J Business Overview
  4. 6.1.3 J & J CAR T-Cell-Based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 J & J CAR T-Cell-Based Drug Product Portfolio
  6. 6.1.5 J & J Recent Developments
  7. 6.2 Novartis
  8. 6.2.1 Novartis Company Information
  9. 6.2.2 Novartis Business Overview
  10. 6.2.3 Novartis CAR T-Cell-Based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Novartis CAR T-Cell-Based Drug Product Portfolio
  12. 6.2.5 Novartis Recent Developments
  13. 6.3 Gilead Sciences
  14. 6.3.1 Gilead Sciences Company Information
  15. 6.3.2 Gilead Sciences Business Overview
  16. 6.3.3 Gilead Sciences CAR T-Cell-Based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Gilead Sciences CAR T-Cell-Based Drug Product Portfolio
  18. 6.3.5 Gilead Sciences Recent Developments
  19. 6.4 Bristol-Myers Squibb
  20. 6.4.1 Bristol-Myers Squibb Company Information
  21. 6.4.2 Bristol-Myers Squibb Business Overview
  22. 6.4.3 Bristol-Myers Squibb CAR T-Cell-Based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Bristol-Myers Squibb CAR T-Cell-Based Drug Product Portfolio
  24. 6.4.5 Bristol-Myers Squibb Recent Developments
  25. 6.5 Sorrento Therapeutics
  26. 6.5.1 Sorrento Therapeutics Company Information
  27. 6.5.2 Sorrento Therapeutics Business Overview
  28. 6.5.3 Sorrento Therapeutics CAR T-Cell-Based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Sorrento Therapeutics CAR T-Cell-Based Drug Product Portfolio
  30. 6.5.5 Sorrento Therapeutics Recent Developments
  31. 6.6 Mustang Bio
  32. 6.6.1 Mustang Bio Company Information
  33. 6.6.2 Mustang Bio Business Overview
  34. 6.6.3 Mustang Bio CAR T-Cell-Based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Mustang Bio CAR T-Cell-Based Drug Product Portfolio
  36. 6.6.5 Mustang Bio Recent Developments
  37. 6.7 JW Therapeutics
  38. 6.7.1 JW Therapeutics Company Information
  39. 6.7.2 JW Therapeutics Business Overview
  40. 6.7.3 JW Therapeutics CAR T-Cell-Based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 JW Therapeutics CAR T-Cell-Based Drug Product Portfolio
  42. 6.7.5 JW Therapeutics Recent Developments
  43. 6.8 FOSUNKite
  44. 6.8.1 FOSUNKite Company Information
  45. 6.8.2 FOSUNKite Business Overview
  46. 6.8.3 FOSUNKite CAR T-Cell-Based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 FOSUNKite CAR T-Cell-Based Drug Product Portfolio
  48. 6.8.5 FOSUNKite Recent Developments
  49. 6.9 Celyad
  50. 6.9.1 Celyad Company Information
  51. 6.9.2 Celyad Business Overview
  52. 6.9.3 Celyad CAR T-Cell-Based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Celyad CAR T-Cell-Based Drug Product Portfolio
  54. 6.9.5 Celyad Recent Developments
  55. 6.10 Cellectis
  56. 6.10.1 Cellectis Company Information
  57. 6.10.2 Cellectis Business Overview
  58. 6.10.3 Cellectis CAR T-Cell-Based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 Cellectis CAR T-Cell-Based Drug Product Portfolio
  60. 6.10.5 Cellectis Recent Developments
  61. 6.11 CARsgen Therapeutics
  62. 6.11.1 CARsgen Therapeutics Company Information
  63. 6.11.2 CARsgen Therapeutics Business Overview
  64. 6.11.3 CARsgen Therapeutics CAR T-Cell-Based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 CARsgen Therapeutics CAR T-Cell-Based Drug Product Portfolio
  66. 6.11.5 CARsgen Therapeutics Recent Developments
  67. 6.12 Bluebird Bio
  68. 6.12.1 Bluebird Bio Company Information
  69. 6.12.2 Bluebird Bio Business Overview
  70. 6.12.3 Bluebird Bio CAR T-Cell-Based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  71. 6.12.4 Bluebird Bio CAR T-Cell-Based Drug Product Portfolio
  72. 6.12.5 Bluebird Bio Recent Developments
  73. 6.13 Autolus Therapeutics
  74. 6.13.1 Autolus Therapeutics Company Information
  75. 6.13.2 Autolus Therapeutics Business Overview
  76. 6.13.3 Autolus Therapeutics CAR T-Cell-Based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  77. 6.13.4 Autolus Therapeutics CAR T-Cell-Based Drug Product Portfolio
  78. 6.13.5 Autolus Therapeutics Recent Developments
  79. 6.14 Allogene Therapeutics
  80. 6.14.1 Allogene Therapeutics Company Information
  81. 6.14.2 Allogene Therapeutics Business Overview
  82. 6.14.3 Allogene Therapeutics CAR T-Cell-Based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  83. 6.14.4 Allogene Therapeutics CAR T-Cell-Based Drug Product Portfolio
  84. 6.14.5 Allogene Therapeutics Recent Developments
7 North America
  1. 7.1 North America CAR T-Cell-Based Drug Market Size (2021-2032)
  2. 7.2 North America CAR T-Cell-Based Drug Market Size by Type
  3. 7.2.1 North America CAR T-Cell-Based Drug Market Size by Type (2021-2026)
  4. 7.2.2 North America CAR T-Cell-Based Drug Market Size by Type (2027-2032)
  5. 7.2.3 North America CAR T-Cell-Based Drug Market Share by Type (2021-2032)
  6. 7.3 North America CAR T-Cell-Based Drug Market Size by Application
  7. 7.3.1 North America CAR T-Cell-Based Drug Market Size by Application (2021-2026)
  8. 7.3.2 North America CAR T-Cell-Based Drug Market Size by Application (2027-2032)
  9. 7.3.3 North America CAR T-Cell-Based Drug Market Share by Application (2021-2032)
  10. 7.4 North America CAR T-Cell-Based Drug Market Size by Country
  11. 7.4.1 North America CAR T-Cell-Based Drug Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America CAR T-Cell-Based Drug Market Size by Country (2021-2026)
  13. 7.4.3 North America CAR T-Cell-Based Drug Market Size by Country (2027-2032)
  14. 7.4.4 North America CAR T-Cell-Based Drug Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe CAR T-Cell-Based Drug Market Size (2021-2032)
  2. 8.2 Europe CAR T-Cell-Based Drug Market Size by Type
  3. 8.2.1 Europe CAR T-Cell-Based Drug Market Size by Type (2021-2026)
  4. 8.2.2 Europe CAR T-Cell-Based Drug Market Size by Type (2027-2032)
  5. 8.2.3 Europe CAR T-Cell-Based Drug Market Share by Type (2021-2032)
  6. 8.3 Europe CAR T-Cell-Based Drug Market Size by Application
  7. 8.3.1 Europe CAR T-Cell-Based Drug Market Size by Application (2021-2026)
  8. 8.3.2 Europe CAR T-Cell-Based Drug Market Size by Application (2027-2032)
  9. 8.3.3 Europe CAR T-Cell-Based Drug Market Share by Application (2021-2032)
  10. 8.4 Europe CAR T-Cell-Based Drug Market Size by Country
  11. 8.4.1 Europe CAR T-Cell-Based Drug Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe CAR T-Cell-Based Drug Market Size by Country (2021-2026)
  13. 8.4.3 Europe CAR T-Cell-Based Drug Market Size by Country (2027-2032)
  14. 8.4.4 Europe CAR T-Cell-Based Drug Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China CAR T-Cell-Based Drug Market Size (2021-2032)
  2. 9.2 China CAR T-Cell-Based Drug Market Size by Type
  3. 9.2.1 China CAR T-Cell-Based Drug Market Size by Type (2021-2026)
  4. 9.2.2 China CAR T-Cell-Based Drug Market Size by Type (2027-2032)
  5. 9.2.3 China CAR T-Cell-Based Drug Market Share by Type (2021-2032)
  6. 9.3 China CAR T-Cell-Based Drug Market Size by Application
  7. 9.3.1 China CAR T-Cell-Based Drug Market Size by Application (2021-2026)
  8. 9.3.2 China CAR T-Cell-Based Drug Market Size by Application (2027-2032)
  9. 9.3.3 China CAR T-Cell-Based Drug Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia CAR T-Cell-Based Drug Market Size (2021-2032)
  2. 10.2 Asia CAR T-Cell-Based Drug Market Size by Type
  3. 10.2.1 Asia CAR T-Cell-Based Drug Market Size by Type (2021-2026)
  4. 10.2.2 Asia CAR T-Cell-Based Drug Market Size by Type (2027-2032)
  5. 10.2.3 Asia CAR T-Cell-Based Drug Market Share by Type (2021-2032)
  6. 10.3 Asia CAR T-Cell-Based Drug Market Size by Application
  7. 10.3.1 Asia CAR T-Cell-Based Drug Market Size by Application (2021-2026)
  8. 10.3.2 Asia CAR T-Cell-Based Drug Market Size by Application (2027-2032)
  9. 10.3.3 Asia CAR T-Cell-Based Drug Market Share by Application (2021-2032)
  10. 10.4 Asia CAR T-Cell-Based Drug Market Size by Country
  11. 10.4.1 Asia CAR T-Cell-Based Drug Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia CAR T-Cell-Based Drug Market Size by Country (2021-2026)
  13. 10.4.3 Asia CAR T-Cell-Based Drug Market Size by Country (2027-2032)
  14. 10.4.4 Asia CAR T-Cell-Based Drug Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa CAR T-Cell-Based Drug Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa CAR T-Cell-Based Drug Market Size by Type
  3. 11.2.1 South America, Middle East & Africa CAR T-Cell-Based Drug Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa CAR T-Cell-Based Drug Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa CAR T-Cell-Based Drug Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa CAR T-Cell-Based Drug Market Size by Application
  7. 11.3.1 South America, Middle East & Africa CAR T-Cell-Based Drug Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa CAR T-Cell-Based Drug Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa CAR T-Cell-Based Drug Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa CAR T-Cell-Based Drug Market Size by Country
  11. 11.4.1 South America, Middle East & Africa CAR T-Cell-Based Drug Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa CAR T-Cell-Based Drug Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa CAR T-Cell-Based Drug Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa CAR T-Cell-Based Drug Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst